Do all we know about the thiazolidinediones, or what pioglitazone differs from rosiglitazone?
- Autores: Mkrtumyan AM1, Mkrtumyan AM1
-
Afiliações:
- Edição: Nº 3 (2009)
- Páginas: 60-64
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/276301
- ID: 276301
Citar
Texto integral
Resumo
We consider the place of thiazolidinediones (TZD; pioglitazone, rosiglitazone) in the treatment of type 2 diabetes mellitus; the mechanisms of their therapeutic action are presented. We discuss the problem of TZD safety in the light of data for adverse events for the cardiovascular system in patients receiving these drugs. Data for the some of the differences in the rosiglitazone and pioglitazone effects on metabolism of fats, which determines a more favorable lipid profile in the case of pioglitazone administration, are presented. We discuss the clinical significance of some side effects of TZD, such as weight gain, fluid retention, etc.
Bibliografia
- Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
- Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370(9593):1129-36.
- Bhatt DL, Chew DP, Grines C, et al. Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization-results of the PPAR study. Am Heart J 2007;154:137-43.
- Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
- Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81.
- Dormandy J, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
- Ryden L, Thrainsdottir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive. Lancet 2007;369:189-90.
Arquivos suplementares
